EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
Teva expands blood pressure drug recall in the US amid cancer fearsTeva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the Share XTeva expands blood pressure drug recall in the US amid cancer fearshttps://pharmaphorum.com/news/teva-expands-blood-pressure-drug-recall-in-the-us-amid-cancer-fears/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
EU regulators slap safety restriction on Pfizer’s XeljanzEuropean safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher Share XEU regulators slap safety restriction on Pfizer’s Xeljanzhttps://pharmaphorum.com/news/eu-regulators-slap-safety-restriction-on-pfizers-xeljanz/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Bayer and J&J settle Xarelto lawsuits in USBayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 Share XBayer and J&J settle Xarelto lawsuits in UShttps://pharmaphorum.com/news/bayer-and-jj-settle-xarelto-lawsuits-in-us/
Acadia faces US federal probe into Nuplazid marketingAcadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into Share XAcadia faces US federal probe into Nuplazid marketinghttps://pharmaphorum.com/news/acadia-faces-us-federal-probe-into-nuplazid-marketing/
Patients switch to lower dose of Pfizer’s RA pill after safety signalPfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in Share XPatients switch to lower dose of Pfizer’s RA pill after safety signalhttps://pharmaphorum.com/news/patients-switch-to-lower-dose-of-pfizers-ra-pill-after-safety-signal/
FDA panel backs J&J’s potential depression blockbusterA panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal Share XFDA panel backs J&J’s potential depression blockbusterhttps://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
